Latest Omicron Strain Targeted in Upcoming Fall COVID-19 Vaccination Campaign

According to the Food and Drug Administration (FDA), the forthcoming round of COVID-19 vaccines will be tailored to combat one of the most recent variations of the coronavirus.

The FDA’s decision follows an endorsement from an external panel of advisors, who recommended modifying the vaccine formulation. Vaccine manufacturers have been directed to ensure protection against a specific strain of omicron, referred to as XBB.1.5.

The current vaccine shots provide immunity against the original coronavirus and an earlier version of omicron. While they still offer defense against severe illness and death, the efficacy gradually diminishes over time. Moreover, these shots have proven less effective against milder infections, even before the virus underwent further evolutionary changes.

In response, the three major U.S. vaccine manufacturers have prepared to adjust their formulas, aiming to produce millions of doses by autumn. Pfizer, one of the companies, expects to have some doses ready as early as next month.

The Centers for Disease Control and Prevention (CDC) will ultimately determine whether the vaccine should be recommended for all Americans or specifically for high-risk groups.

The Howard Hughes Medical Institute’s Science and Educational Media Group provides support to The Big Big News Health and Science Department. The AP is solely responsible for all content.

Frequently Asked Questions (FAQs) about COVID-19 vaccines

More about COVID-19 vaccines

• FDA
• Centers for Disease Control and Prevention (CDC)
• Pfizer
• Howard Hughes Medical Institute